BioCentury | Mar 24, 2018
Product Development

Optimism for A2A

...to enter the clinic this year; Source: BCIQ: BioCentury Online Intelligence Company Compound Phase Indication Palobiofarma S.L....
BioCentury | Mar 31, 2016
Distillery Therapeutics

Therapeutics: Adenosine A1 receptor (ADORA1)

...include testing efficacy and safety of the nanoparticle conjugate in various models of respiratory complications. Palobiofarma S.L....
BioCentury | Oct 26, 2015
Company News

Palobiofarma, Novartis deal

...Palobiofarma granted Novartis exclusive, worldwide rights to develop and commercialize PBF-509 . Palobiofarma said the adenosine...
...company also granted Novartis rights to IP related to the role of adenosine in immunotherapy. Palobiofarma...
...double-digit royalties. Palobiofarma did not respond to inquiries, and Novartis declined to disclose additional terms. Palobiofarma S.L....
BioCentury | Oct 22, 2015
Company News

Novartis strikes cancer deals with Admune, Palobiofarma

...Mass.) and obtained exclusive, worldwide rights to non-small cell lung cancer (NSCLC) candidate PBF-509 from Palobiofarma S.L....
...Novartis declined to disclose financial terms of the deal (see BioCentury, May 4, 2015) . Palobiofarma...
...company also granted Novartis rights to IP related to the role of adenosine in immunotherapy. Palobiofarma...
BioCentury | Aug 17, 2015
Product Development

Structure knows best

...likely be the second A2A antagonist to enter the clinic for cancer. According to ClinicalTrials.gov, Palobiofarma S.L....
...Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Palobiofarma S.L....
Items per page:
1 - 5 of 5
BioCentury | Mar 24, 2018
Product Development

Optimism for A2A

...to enter the clinic this year; Source: BCIQ: BioCentury Online Intelligence Company Compound Phase Indication Palobiofarma S.L....
BioCentury | Mar 31, 2016
Distillery Therapeutics

Therapeutics: Adenosine A1 receptor (ADORA1)

...include testing efficacy and safety of the nanoparticle conjugate in various models of respiratory complications. Palobiofarma S.L....
BioCentury | Oct 26, 2015
Company News

Palobiofarma, Novartis deal

...Palobiofarma granted Novartis exclusive, worldwide rights to develop and commercialize PBF-509 . Palobiofarma said the adenosine...
...company also granted Novartis rights to IP related to the role of adenosine in immunotherapy. Palobiofarma...
...double-digit royalties. Palobiofarma did not respond to inquiries, and Novartis declined to disclose additional terms. Palobiofarma S.L....
BioCentury | Oct 22, 2015
Company News

Novartis strikes cancer deals with Admune, Palobiofarma

...Mass.) and obtained exclusive, worldwide rights to non-small cell lung cancer (NSCLC) candidate PBF-509 from Palobiofarma S.L....
...Novartis declined to disclose financial terms of the deal (see BioCentury, May 4, 2015) . Palobiofarma...
...company also granted Novartis rights to IP related to the role of adenosine in immunotherapy. Palobiofarma...
BioCentury | Aug 17, 2015
Product Development

Structure knows best

...likely be the second A2A antagonist to enter the clinic for cancer. According to ClinicalTrials.gov, Palobiofarma S.L....
...Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Palobiofarma S.L....
Items per page:
1 - 5 of 5